| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 168.92 | 18.1% |
| Total Income | 174.15 | 17.6% |
| Expenditure | 138.72 | 12.6% |
| PBT | 35.43 | 73.7% |
| Net Profit | 26.29 | 77.6% |
| OPM | 21.00% | 73.62pp |
| NPM | 15.10% | 64.11pp |
| EPS | 15.90 | 77.6% |
RPG Life Sciences Q1 FY26: Revenue up by 2.1% Y-o-Y, EBITDA margin at 24.1%
25 Jul 2025 · 25 Jul 2025, 07:52 pm
Summary
RPG Life Sciences Limited has announced its financial results for the first quarter ended June 30, 2025. The company's revenue from operations has increased by 2.1% Y-o-Y to Rs. 168.9 crores and EBITDA margin stands at 24.1%. Profit before tax remained largely in line with the previous year.
Key Highlights
- 1
Revenue from operations: Rs. 168.9 crores vs. Rs. 165.4 crores
- 2
Profit before tax: Rs. 35.4 crores vs. Rs. 36.0 crores
- 3
2.1% Y-o-Y increase in sales
- 4
Healthy EBITDA margin of 24.1%
- 5
Domestic Formulations business continues to deliver market-beating growth
- 6
Actively exploring inorganic growth opportunities across both formulations and APIs
Management Comments
Mr. Ashok Nair
In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach.
Informational and educational content only. Not investment advice.